WALTHAM, Mass.–(BUSINESS WIRE)–Sep. 4, 2020– PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the BofA Global Healthcare Conference 2020 on Wednesday, September 16, 2020 at 10:05 a.m. ET. Prahlad Singh, president and chief executive officer of PerkinElmer, will provide an overview... Read more
First commercial test for fully automated high throughput systems to detect and differentiate SARS-CoV-2, influenza A virus and/or influenza B virus with a single sample As COVID-19 and influenza infections can hardly be differentiated based on symptoms, healthcare professionals can confidently provide the right diagnosis and best course of treatment for patients Test for use... Read more
Researchers at Washington University in St. Louis find an easier way to quantify synaptic loci The brain’s vast synaptic network with billions of neurons making trillions of connections in a very dense matrix continues to challenge scientists who wish to decipher its intricacies in the context of brain health and disease. Established approaches using electron... Read more
CAMBRIDGE, Angleterre–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ : ILMN) a annoncé aujourd’hui une collaboration avec 54gene, une société de technologie de la santé dont la mission consiste à faire progresser les capacités de la médecine de précision en Afrique grâce à la recherche, des diagnostics moléculaires avancés et des programmes cliniques. Le partenariat permettra la création de nouvelles... Read more
CAMBRIDGE, Inglaterra–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) ha anunciado hoy una colaboración con 54gene, una empresa de tecnología sanitaria cuya misión es hacer avanzar las capacidades de la medicina de precisión en África a través de la investigación, los diagnósticos moleculares avanzados y los programas clínicos. La asociación ayudará a la creación de una nueva instalación... Read more
CAMBRIDGE, England–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) gab heute eine Zusammenarbeit mit 54gene bekannt, einem Unternehmen der Gesundheitstechnologie, dessen Aufgabe es ist, die Fähigkeiten der Präzisionsmedizin in Afrika durch Forschung, fortschrittliche molekulare Diagnostik und klinische Programme zu fördern. Die Partnerschaft wird die Einrichtung einer neuen Genetik-Einrichtung in Lagos, Nigeria, unterstützen, die mit einer Reihe von Illuminas... Read more
CAMBRIDGE, Inghilterra–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) ha annunciato oggi una collaborazione con 54gene, società operante nel campo delle tecnologie sanitarie la cui missione è promuovere le competenze della medicina di precisione in Africa attraverso ricerca, diagnostica molecolare avanzata e programmi clinici. La partnership sosterrà la creazione di un nuovo centro di genetica a Lagos, in... Read more
CAMBRIDGE, Engeland–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) kondigde vandaag een samenwerking aan met 54gene, een gezondheidstechnologiebedrijf dat tot doel heeft de capaciteiten van precisiegeneeskunde in Afrika te vergroten door middel van onderzoek, geavanceerde moleculaire diagnostiek en klinische programma’s. Het partnerschap ondersteunt de oprichting van een nieuwe genetica-faciliteit in Lagos, Nigeria, uitgerust met een reeks van Illumina’s... Read more
CAMBRIDGE, England–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) today announced a collaboration with 54gene, a health technology company whose mission is to advance precision medicine capabilities in Africa through research, advanced molecular diagnostics and clinical programs. The partnership will support the establishment of a new genetics facility in Lagos, Nigeria, equipped with a suite of Illumina’s cutting-edge... Read more
New data further reinforce OCREVUS (ocrelizumab) as a highly effective treatment option offering a favourable and consistent benefit:risk profile, with high treatment persistence and adherence Initiation of Phase IIIb OCREVUS higher dose clinical trial programme and Phase IV study evaluating OCREVUS in minority populations Initiation of Phase III clinical trial programme for fenebrutinib, an investigational... Read more